Scarica l'app Stockscreener
0.6703
5.53%
-0.0392
Dopo l'orario di chiusura:
.70
0.0297
+4.43%
Precedente Chiudi:
$0.7095
Aprire:
$0.7
Volume 24 ore:
143.07K
Relative Volume:
0.42
Capitalizzazione di mercato:
$14.02M
Reddito:
-
Utile/perdita netta:
$-14.58M
Rapporto P/E:
-0.5829
EPS:
-1.15
Flusso di cassa netto:
$-9.80M
1 W Prestazione:
-20.94%
1M Prestazione:
-8.19%
6M Prestazione:
-68.08%
1 anno Prestazione:
-77.35%
Intervallo 1D:
$0.67
$0.7199
Intervallo di 1 settimana:
$0.67
$0.85
Portata 52W:
$0.669
$3.325
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Nome
Acurx Pharmaceuticals Inc
Settore
Industria
Telefono
917-533-1469
Indirizzo
259 LIBERTY AVENUE, STATEN ISLAND
Confronta ACXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
0.6703 | 14.02M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acurx Pharmaceuticals Inc Borsa (ACXP) Ultime notizie
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics - Longview News-Journal
What's Next for Acurx's Antibiotic Pipeline? March Earnings Call Will Reveal Development Progress - StockTitan
Biotech Alert: Searches spiking for these stocks today - TipRanks
Acurx’s ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals Advances To Phase 3 Trials For C. Difficile Infection, Stock Down - Nasdaq
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the - Digital More
Acurx's ibezapolstat shows selective bacterial targeting By Investing.com - Investing.com South Africa
Acurx's ibezapolstat shows selective bacterial targeting - Investing.com
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI - Longview News-Journal
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative… - Informazione.it
ACXP stock touches 52-week low at $0.67 amid market challenges - Investing.com UK
Acurx Pharmaceuticals secures Japanese patent for antibiotics By Investing.com - Investing.com South Africa
Acurx Pharmaceuticals secures Japanese patent for antibiotics - Investing.com India
Dual Victory for Acurx: Japanese Patent Grant Follows EMA's Green Light for Phase 3 Antibiotic Trial - StockTitan
New to the Street to Broadcast Show 627 on Bloomberg Television at 6:30 PM EST Today as Sponsored Programming - StreetInsider.com
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Drops By 52.2% - Defense World
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Decline in Short Interest - Armenian Reporter
Acurx Pharmaceuticals Says Selling Shareholders May Sell 2.6 Million Shares -January 31, 2025 at 05:06 pm EST - Marketscreener.com
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update - Defense World
New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH) - ACCESS Newswire
Geode Capital Management LLC Increases Stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Acurx Pharmaceuticals Inc (ACXP) - SETE News
HC Wainwright Reaffirms Buy Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals (NASDAQ: ACXP) Announces $2.5 Million Registered Direct Offering - Defense World
Acurx pharmaceuticals director Carl Sailer acquires shares worth $25,000 - Investing.com
Acurx pharmaceuticals director Joseph Scodari acquires $25,000 in stock - Investing.com
Acurx pharmaceuticals director Carl Sailer acquires shares worth $25,000 By Investing.com - Investing.com UK
Acurx Pharmaceuticals director buys $9,999 in common stock - Investing.com
Acurx Pharmaceuticals director Robert DeLucca buys $49,999 in stock By Investing.com - Investing.com South Africa
ACXP stock touches 52-week low at $0.72 amid market challenges - Investing.com Canada
Acurx Pharmaceuticals Secures $2.5M Financing Through Direct Offering and Warrant Placement - StockTitan
Form 424B5 Acurx Pharmaceuticals, - StreetInsider.com
SEC Form 424B5 filed by Acurx Pharmaceuticals Inc. - Quantisnow
Acurx to sell 2.46M shares at $1.015 in registered direct offering - MSN
Acurx gains EMA support for ibezapolstat Phase 3 trial By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals announces $2.5 million registered direct offering - MSN
Acurx gains EMA support for ibezapolstat Phase 3 trial - Investing.com
Acurx's Ibezapolstat Secures EMA Backing for Phase 3 C. Difficile Treatment Program - StockTitan
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? - Yahoo Finance
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Increase in Short Interest - Defense World
Acurx Pharmaceuticals to Present Latest Antibiotic Developments at 2025 Microcap Conference - StockTitan
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025January 30, 2025 - Eagle-Tribune
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 - Kilgore News Herald
Acurx prepares for Phase 3 trials in C. difficile treatment By Investing.com - Investing.com Canada
Acurx prepares for Phase 3 trials in C. difficile treatment - Investing.com India
Acurx's Breakthrough CDI Antibiotic Advances Toward Global Phase 3 Trial Following FDA Green Light - StockTitan
ACXP stock touches 52-week low at $0.79 amid market challenges - Investing.com UK
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now - MSN
ACXP stock touches 52-week low at $1.01 amid market challenges - Investing.com Canada
Acurx Pharmaceuticals Inc Azioni (ACXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acurx Pharmaceuticals Inc Azioni (ACXP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sailer Carl | Director |
Jan 06 '25 |
Buy |
1.01 |
24,631 |
25,000 |
137,183 |
| LUCI DAVID P | President and CEO |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,097,458 |
| Donohue James J. | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
22,352 |
| DELUCCIA ROBERT J | Director |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,010,196 |
| DEAN JACK H | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
21,776 |
6.45%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):